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Somatic	activating	mutations	in	Notch1	contribute	to	the	pathogenesis	of	T	cell	acute	lymphoblastic	lym-
phoma	(T-ALL),	but	how	activated	Notch1	signaling	exerts	this	oncogenic	effect	is	not	completely	under-
stood.	Here	we	identify	HIV-1	Rev–binding	protein	(Hrb),	a	component	of	the	clathrin-mediated	endocytosis	
machinery,	as	a	critical	mediator	of	Notch-induced	T-ALL	development	in	mice.	Hrb	was	found	to	be	a	direct	
transcriptional	target	of	Notch1,	and	Hrb	loss	reduced	the	incidence	or	delayed	the	onset	of	T-ALL	in	mouse	
models	in	which	activated	Notch1	signaling	either	contributes	to	or	drives	leukemogenesis.	Consistent	with	
this	observation,	Hrb	supported	survival	and	proliferation	of	hematopoietic	and	T	cell	precursor	cells	in	
vitro.	We	demonstrated	that	Hrb	accelerated	the	uptake	of	transferrin,	which	was	required	for	upregulation	
of	the	T	cell	protooncogene	p21.	Indeed,	iron-deficient	mice	developed	Notch1-induced	T-ALL	substantially	
more	slowly	than	control	mice,	further	supporting	a	critical	role	for	iron	uptake	during	leukemogenesis.	
Taken	together,	these	results	reveal	that	Hrb	is	a	critical	Notch	target	gene	that	mediates	lymphoblast	trans-
formation	and	disease	progression	via	its	ability	to	satisfy	the	enhanced	demands	of	transformed	lympho-
blasts	for	iron.	Further,	our	data	suggest	that	Hrb	may	be	targeted	to	improve	current	treatment	or	design	
novel	therapies	for	human	T-ALL	patients.
Introduction
T  cell  acute  lymphoblastic  lymphoma  (T-ALL)  are  serious 
hematologic malignancies of children and young adults. Cur-
rent treatments that include intensive chemotherapy and cra-
nial radiation are unsatisfactory, as they frequently cause severe 
long-term  toxicities.  Furthermore,  significant  numbers  of 
patients die from recurrent disease, in spite of therapy. Better 
understanding of the molecular basis of lymphomagenesis will 
likely lead to improved therapy. The Notch receptor is impli-
cated in the pathogenesis of T-ALL (1–3). Recent studies have 
demonstrated that Notch1 is activated by somatic mutations in 
approximately 60% of cases of pediatric T-ALL (4). Notch1 is a 
cell surface receptor that is activated by ligands from the DSL 
family. Ligand binding induces proteolytic cleavage of Notch1 
(S2), which  is  immediately  followed by  further  cleavage  by 
gamma-secretase (S3). This cleavage results in the release of the 
soluble Notch1 intracellular domain (ICN1), which translocates 
to the nucleus, where it activates transcription of target genes 
via its interaction with the DNA-binding protein CSL.
How Notch transforms T cell precursors remains a subject of 
intense study. Activated Notch has multiple pleiotropic effects in 
T cell precursors, which include dramatic acceleration of prolifera-
tion, increased thymocyte survival, and a block in differentiation 
(5). Preliminary studies on Notch inhibition by gamma-secretase 
inhibitors (GSIs) have demonstrated the importance of this signal-
ing pathway in T-ALL. However, systemic toxicity limits the use of 
these drugs, and current efforts by many investigators focus on the 
downstream molecular sequelae of Notch activation with the hope 
that they may provide useful therapeutic targets.
In previous studies, we found that mice bearing a conditional 
knockout allele of Creb-binding protein (CBP) developed fatal 
T cell lymphomas with high penetrance. The transformed cells 
resembled  immature  thymocytes  and had a CD4+CD8+ dou-
ble-positive (DP) phenotype (6). Microarray analyses revealed 
upregulation of multiple transcripts, including components of 
the Notch signaling pathway, c-myc, and the HIV-1 Rev–binding 
protein (Hrb). Hrb is an essential cofactor for HIV replication 
(7–9) and serves as an AP-2/EPS15 adapter required for vesicle 
fusion events that create the acrosome during spermatogenesis 
(10). Additionally, Hrb is implicated in clathrin-dependent endo-
cytosis of VAMP7 (11) and the transferrin receptor (TfR) (12). 
However,  it has not been implicated in oncogenesis. Here, we 
identify what we believe is a novel role for Hrb in T cell lymphom-
agenesis and find that it contributes significantly through its 
effects on transferrin uptake. In addition, we demonstrate what 
we believe is a novel function of Hrb in regulating protein levels 
of the T cell prosurvival factor p21 (WAF1/CIP1).
Results
Notch activation cooperates with CBP loss to accelerate T cell lymphomagenesis. 
We previously observed that transcriptional targets of Notch1 
were upregulated in the majority of CBP-null T cell lymphomas 
(6), raising the possibility that activated Notch might have been a 
contributing factor to their development. If Notch indeed cooper-
ates with CBP loss, then activation of Notch by use of a transgene 
might accelerate T cell lymphomagenesis in CBP-null mice. Thus, 
we generated mice that had both a conditional deletion of CBP and 
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that expressed the intracellular activated form of Notch1 (ICN1) 
(13). ICN1 transgenic mice developed T cell lymphomas around 98 
weeks (data not shown). Mice with the ICN1 transgene combined 
with CBP loss developed T cell lymphomas much faster than lit-
termate control animals that were singly CBP-null or ICN1-trans-
genic (P < 0.0001 by Mantel-Cox log-rank analysis) (Figure 1A), 
consistent with the notion that activated Notch could synergize 
with loss of CBP to generate T cell lymphoma.
Hrb is a direct transcriptional target of Notch1. Hrb mRNA levels were 
significantly elevated in T cell lymphomas from CBP-null mice (6). 
To verify whether this was also reflected at the protein level, we pre-
pared lysates from 6 independent spontaneous T cell lymphomas 
from CBP-null mice and analyzed Hrb protein by Western blotting. 
Five out of 6 tumors expressed dramatically higher levels of Hrb 
protein compared with nontransformed thymocytes (Figure 1B).
In an independent study, Weng et al. investigated changes in 
gene  expression  in T-ALL  cells  following Notch1  inhibition. 
Among their results was the finding that Hrb transcript levels were 
reduced following Notch inactivation (14). In addition, microarray 
analyses of several murine T-ALL cell lines have consistently shown 
Hrb to be regulated by Notch1 (W.S. Pear, unpublished observa-
tions). To address whether Hrb is directly regulated by Notch1 
signaling, we utilized the Notch-dependent murine T-ALL cell 
line T6E12 (15). Transfection of cells with a dominant negative 
MAML1 construct (DNMAML1) or treatment with GSI decreased 
Hrb mRNA and protein levels (Figure 2B), accompanied by pro-
gressive cell growth arrest/death. Expression of a constitutively 
active, GSI-insensitive form of Notch1, ICN1, restored Hrb mRNA 
levels even in the presence of GSI. Treatment of T-ALL cells with 
GSI resulted in the accumulation of a transmembrane-tethered 
form of Notch that can be rapidly cleaved to the intracellular acti-
vated form (ICN1) upon GSI removal. GSI washout resulted in 
the derepression of Hrb mRNA, even in the presence of the pro-
tein synthesis inhibitor cycloheximide, suggesting that Hrb could 
be a direct transcriptional target of Notch1 (Figure 2B). Analysis 
of the Hrb gene revealed CSL-binding sites approximately 32 kb 
upstream of the Hrb promoter (site A: –32 kb, TGTGGGAA) and 
following exon 1 in the first intron (site B: +180 bp, CGTGGGTA), 
which could potentially allow Notch1 to initiate transcription of 
the gene. Using ChIP, we detected CSL binding to both of these 
sites (Figure 2C), albeit much stronger at site A. GSI treatment 
depleted ICN1 from these sites. These data strongly suggest that 
Notch1 acts directly to induce Hrb transcription. We also observed 
that Hrb transcript levels were highest during the double-negative 
(DN) stage of thymocyte development when Notch signaling is 
believed to be most active. These levels subsequently dropped dur-
ing the DP stage, when Notch is believed to be turned off (Supple-
mental Figure 6; supplemental material available online with this 
article; doi:10.1172/JCI41277DS1).
Next, we asked whether Notch1 signaling would significantly 
alter the protein levels of Hrb in a primary T cell system. Thy-
mocytes were prepared from WT mice and sorted to purify the 
earliest thymic-precursor CD4–CD8– DN cells. These were seed-
ed onto irradiated beds of OP9DL1 cells to provide low-level 
Notch stimulation that would allow their survival and prolif-
eration (16). Expression of activated (oncogenic) Notch1 was 
enforced by transduction with a retrovirus (Mig-ICN1). In these 
conditions, Hrb protein levels were dramatically increased (Fig-
ure 2D). Together, these experiments suggested that elevated 
Notch1 signaling in T cell lymphomas was responsible for the 
high-level expression of Hrb.
Hrb is crucial for CBP-null lymphomagenesis. To explore whether Hrb 
might participate in oncogenesis, we generated cohorts of Hrb+/+ 
and Hrb–/– mice in addition to conditional deletion of CBP in the 
thymus. These mice were followed for up to 90 weeks. We observed 
a 70% reduction in the incidence of T cell lymphomas in the Hrb–/– 
mice in comparison with Hrb+/+ littermate controls (15% vs. 50%, 
P = 0.0396 by Mantel-Cox log rank analysis) (Figure 3A), indicating 
that Hrb plays a critically important role in efficient tumor forma-
tion due to loss of CBP in thymocytes.
Hrb expression was highly induced above basal levels in all lym-
phomas that had Notch1 upregulation (Figure 3B). However, Hrb 
could also be induced by alternative pathways, since high-level Hrb 
was detected in some tumors lacking Notch1 (Figure 3B). Addi-
tionally, the upregulation of Hrb in CBP-null tumors correlated 
with Notch activation as demonstrated with an antibody that 
detects the gamma-secretase cleaved form of Notch1 (Figure 3C).
Hrb is not required for physiologic Notch signaling. Although the ini-
tial site of transformation in T-ALL is not known, we postulated 
that either a committed lymphoid precursor in the BM or an early-
stage thymocyte would be a likely candidate target cell, because 
of the phenotype of most lymphoma cells that arise in CBP-null 
or Notch-transgenic mice (CD4-positive, CD8-positive). If loss of 
the Hrb gene would cause a defect in thymocyte development, this 
would be a relatively trivial mechanism underlying its protective 
effect in preventing T-ALL in the absence of CBP (Figure 3A). To 
test this possibility, we examined thymi from Hrb+/+, Hrb+/–, and 
Hrb–/– mice. These studies revealed an equal number of total thy-
Figure 1
Notch activation cooperates with CBP loss to accelerate lymphoma-
genesis. (A) Kaplan-Meier survival curve of mice with either (a) condi-
tional deletion of CBPflox/flox via an MMTV-Cre mediated excision (n = 9), 
(b) transgenic expression of ICN1 via MMTV-Cre mediated excision 
of a floxed STOP sequence sandwiched between the chicken β-actin 
promoter and ICN1 coding sequence (n = 11), or (c) transgenic for 
ICN1 expression and CBP-null (n = 17). P < 0.0001 using log-rank 
(Mantel-Cox) test. ICN1 transgenic mice developed T cell lymphomas 
around 98 weeks. (B) Western blot of lysates prepared from control 
thymocytes and 6 CBP-null T cell lymphomas, blotting for Hrb (clone 
386–562) and actin (loading control).
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Figure 2
Hrb is a direct Notch1-regulated transcriptional target. (A) A murine Notch-dependent cell line, T6E12, was utilized for Hrb mRNA and protein 
analysis. T6E12 cells were transduced with MigR1 (empty vector), MigR1-ICN1, or MigR1-DNMAML1 for 48 hours followed by 24 hours DMSO 
or GSI (1 μM) treatment as labeled. Hrb mRNA and protein levels were determined by quantitative RT-PCR and Western blot analysis, respec-
tively. Results were obtained from 3 independent experiments. (B) T6E12 cells were treated with GSI (1 μM) for 48 hours to permit accumulation 
of the gamma-secretase substrate (transmembrane-Notch1 [NTM]). Cells were then washed and replenished with medium containing GSI (mock 
washout) or medium lacking GSI (washout) in the absence or presence of 20 μM cycloheximide (CHX). Hrb mRNA levels were evaluated by 
quantitative RT-PCR after 4 hours of additional incubation. Similar results were obtained in 3 independent experiments. (C) ChIP was performed 
on cross-linked fragmented DNAs prepared from T6E12 cells treated with DMSO or 1 μM GSI for 24 hours. Eluted DNAs were then analyzed 
by quantitative RT-PCR using primers flanking putative CSL-binding sites (A and B). Amplification of hes1 CSL-binding site served as a positive 
control to validate ChIP efficiency. The amount of DNA amplified from immunoprecipitated DNAs was normalized to that amplified from input 
DNA. (D) Western blot of lysates prepared from empty vector– (MigR1) and ICN1-transduced Hrb+/+ and Hrb–/– T cell precursors blotted for Hrb 
(clone H-300) and actin (loading control). Asterisk indicates nonspecific band. Data are shown as mean ± SD.
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mocytes (Supplemental Figure 1A), and also completely normal 
CD4–CD8– DN (Supplemental Figure 1B), CD4+CD8+ DP, CD4+ 
single-positive (SP), and CD8+ SP subsets (Supplemental Figure 
1C). In addition, analysis of the TCR-β repertoire by an RT-PCR 
method (17) revealed results virtually identical to those from Hrb+/+ 
and Hrb–/– splenocytes. We conclude that Hrb is not required for 
normal thymocyte development at various stages. Finally, Hrb 
was not required for expansion of stimulated peripheral T cells 
(Supplemental Figure 4).
Hrb is required for efficient ICN1-induced leukemogenesis. Since Hrb 
is a direct transcriptional target of Notch and Notch activation 
cooperates with CBP loss to accelerate lymphomagenesis, we asked 
whether Hrb participates in Notch-induced tumorigenesis using 
a well-characterized BM transduction and transplantation model 
(18). Hrb–/– and littermate control mice were treated with 5-FU 
to enrich for hematopoietic stem cells, which were transduced 
with control virus (MigR1) or ICN1-expressing retrovirus. Equal 
transduction efficiencies were verified by flow cytometric detection 
of GFP (Figure 4A) and semiquantitative RT-PCR of ICN1 mRNA 
(data not shown). Transduced BM cells were transferred to lethally 
irradiated wild-type recipients, which were then observed for onset 
of T-ALL over the next several months. These experiments revealed 
a clear requirement for Hrb in efficient ICN1-induced leukemo-
genesis (Figure 4B). The median survival of mice receiving Hrb+/+ 
ICN1–transduced BM was 27.5 days after BM transplant (BMT). 
Median survival of mice receiving Hrb–/– ICN1–transduced BM was 
approximately 2-fold longer at 54.0 days after transplant (P < 0.0001 
by Mantel-Cox log rank analysis). Mice that received control ret-
rovirus-transduced BM cells of either WT or Hrb–/– genotype did 
not develop leukemia and had normal engraftment and survival. 
Analysis of the peripheral blood from transplant recipients 15 
days after BMT revealed an accumulation of GFP+ DP cells in both 
Hrb+/+ ICN1 and Hrb–/– ICN1 recipients (Figure 4C). Additionally, 
splenocyte (Figure 4D) and BM (Figure 4E) analyses performed 26 
days after BMT also showed an equal accumulation of GFP+ DP 
cells in both Hrb+/+ and Hrb–/– ICN1–transduced BM recipients. 
Thus, we do not suspect that the significant delay in development 
of T-ALL in Hrb–/– cells was a result of failed engraftment. BM iso-
lated from Hrb–/– ICN1 transplants did show reduced numbers 
of GFP+ cells and an increased percentage of GFP+CD8+ SP cells 
(Supplemental Figure 5).
Hrb is required for growth and survival of ICN1-transduced hematopoi-
etic and T cell precursors. To investigate the mechanism of Hrb in 
oncogenic Notch signaling, we cultured hematopoietic precursors 
from Hrb+/+ and Hrb–/– BM on OP9 stromal cells, transduced with 
ICN1, and then monitored cells for growth over a period of 7 days. 
ICN1-transduced BM cells that were Hrb–/– had reduced growth 
and increased death as measured by annexin V/propidium iodide 
(PI) staining, compared with Hrb+/+ cells (Figure 5, A and B). Retro-
viral mediated reexpression of Hrb rescued both defects. Next, we 
isolated CD4–CD8– DN thymocytes from Hrb+/+ and Hrb–/– mice 
and plated these T cell precursors onto OP9DL1 stromal cells. 
Upon transduction with ICN1, loss of Hrb was associated with a 
marked reduction in cell numbers in all 3 thymocyte subsets (DN, 
CD8 immature SP [ISP], and DP) that developed after 5 days in 
these cocultures, in comparison with wild-type cells (Figure 5C). 
We verified that Hrb protein levels were significantly upregulated 
in both hematopoietic precursors and T cell precursors (Figure 5D) 
transduced with ICN1.
Hrb loss increases surface CD71 and is required for efficient transfer-
rin uptake. Hrb is important for the internalization of cell surface 
VAMP7 and delivery to the lysosomal membrane (11) and effi-
cient clathrin-dependent endocytosis (12). The TfR (CD71) is a 
well-known substrate for clathrin-dependent endocytosis (19–22), 
and its endocytosis and trafficking are critically important for its 
essential role in cellular uptake of iron in the form of holo-trans-
ferrin. Intriguingly, transferrin and TfR have both been implicat-
ed in thymocyte development (23–25) and TfR has been found to 
be elevated on immature cycling thymocytes (26) and leukemias 
(27, 28). Therefore, we asked whether Hrb might participate in 
regulation of CD71 in the context of oncogenic Notch signal-
ing. DN thymocytes cultured on OP9DL1 cells were transduced 
with control or ICN1-expressing retrovirus and cultured for 5 
days. CD71 at the cell surface detected by flow cytometry after 
antibody staining revealed several important findings. First, DN 
cells had higher levels of CD71 than subsequent developmental 
Figure 3
Hrb is required for efficient CBP-null lymphomagenesis. (A) Kaplan-Meier survival curve of Hrb+/+ and Hrb–/– cohorts monitored over a period 
of 90 weeks. Hrb+/– mice on the background of MMTV-Cre/CBPflox/flox were intercrossed to generate Hrb+/+ and Hrb–/– mice with conditional 
loss of CBP. Mice were sacrificed once moribund and confirmed via dissection for the occurrence of T cell lymphoma (n = 19 for each cohort; 
P = 0.0396, log-rank Mantel-Cox test). (B) Western blot of lysates prepared from Hrb+/+ CBP-null tumors (n = 7) and Hrb–/– CBP-null tumors 
(n = 2). Membrane was blotted for Notch1 protein (clone mN1a), Hrb (clone H-300), and GAPDH (loading control). (C) Western blot of lysates 
prepared from CBP-null tumors (n = 3) and control thymocytes (n = 2). Membrane was blotted for activated Notch (VAL1744 Ab), Hrb (clone 
H-300), and actin (loading control). Asterisks indicate nonspecific bands.
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stages, consistent with their high rates of proliferation (29). Fur-
thermore, ICN1 expression induced higher levels of CD71 at each 
developmental stage (Figure 6A). The most striking finding was 
that Hrb–/– cells, either with or without ICN1, had higher surface 
CD71 than Hrb+/+ cells (Figure 6A). Hrb–/– BM hematopoietic pre-
cursors transduced with ICN1 also expressed significantly higher 
surface CD71 compared with WT controls (Figure 6B). The high 
levels of surface CD71 in knockout cells was reduced to WT levels 
with reexpression of Hrb.
To test the function of CD71, cells were incubated with fluo-
rescently labeled transferrin for various periods of time, washed, 
and then analyzed by flow cytometry to detect uptake. As expect-
ed from the increased surface CD71, expression of ICN1 caused a 
more rapid and greater final uptake of transferrin both in WT and 
in Hrb–/– cells compared with MigR1-transduced cells (Figure 6, 
C and D). Loss of Hrb in ICN1-expressing DP cells caused a rela-
tive reduction in the uptake of transferrin, in spite of their slightly 
higher CD71 levels. In the case of ICN1-transduced DN and CD8 
ISP cells, transferrin uptake was equal between Hrb–/– and Hrb+/+ 
cells (Supplemental Figure 2, A and B), even though there were 
significantly higher CD71 levels on the Hrb–/– cells. Together, these 
studies suggest that transferrin uptake is less efficient in cells lack-
ing Hrb if they also express ICN1.
Efficient transferrin uptake and subsequent utilization of iron 
are essential for rapidly growing cells in order to support cell divi-
sion. We wondered, therefore, whether the defect in proliferation 
and survival seen in ICN1-expressing Hrb–/– cells could, in part, be 
explained by insufficient availability of transferrin. Although the 
mutant cells had inefficient uptake, we found that increasing the 
extracellular transferrin did lead to increased uptake (Figure 6D). 
To bypass the Hrb–/– defect, we cultured hematopoietic precursors 
transduced with ICN1 in the presence of excess transferrin. Under 
these conditions, mutant cells recovered their ability to proliferate 
in vitro, while the addition of excess transferrin had little effect on 
WT cells (Figure 6E). This was accompanied by a significant reduc-
tion in cell surface CD71 as well (Figure 6F). To further confirm 
that iron supplementation can rescue the defect in Hrb–/– ICN1–
transduced cells, we incubated DN T cell precursors with ferric 
ammonium citrate (FAC), a compound that stimulates a trans-
ferrin-independent uptake of iron (30). Similar to the results of 
holo-transferrin addition, FAC addition rescued the Hrb–/– defect 
in proliferation, but had little effect on WT cells (Supplemental 
Figure 3). These results strongly suggested that inefficient iron 
utilization was a major factor limiting the proliferation and sur-
vival of ICN1-expressing Hrb–/– cells.
Consistent with the increased surface expression of CD71 fol-
lowing ICN1 transduction, total cellular levels of CD71 were also 
induced compared with MigR1 controls (Figure 6G). Poor trans-
ferrin uptake and/or trafficking in the absence of Hrb might 
explain why CD71  levels were higher on mutant cells,  since 
translation of the TfR mRNA is increased when intracellular 
levels of iron are low. Western blotting indicated that total cel-
lular levels of CD71 were indeed elevated in Hrb–/– MigR1– and 
ICN1–transduced cells (Figure 6G). As predicted, total cellular 
CD71 in Hrb–/– ICN1–transduced cells decreased in the presence 
of excess holo-transferrin.
Figure 4
Hrb is required for efficient ICN1-induced leukemogenesis. 
(A) Analysis of GFP expression in Hrb+/+ and Hrb–/– BM 
after transduction with ICN1-expressing retrovirus and 
before transplantation into lethally irradiated recipients. 
Numbers in each GFP histogram refer to the GFP-posi-
tive percentage. (B) Kaplan-Meier survival curve of 
mice receiving Hrb+/+ ICN1–transduced BM (n = 10), 
Hrb–/– ICN1–transduced BM (n = 13), Hrb+/+ MigR1–
transduced BM (n = 4), and Hrb–/– MigR1–transduced 
BM (n = 4). Statistical significance was established 
using the Mantel-Cox log rank analysis and showed 
a significant increase in survival in mice receiving 
Hrb–/– ICN1–transduced BM (P < 0.0001). Median time 
of survival after BMT for mice receiving Hrb+/+ ICN1–
transduced BM was 27.5 days. Median time of survival 
after BMT for mice receiving Hrb–/– ICN1–transduced 
BM was 54 days. Mice receiving MigR1-transduced 
BM did not succumb to disease. (C) GFP analysis and 
CD4+CD8+ surface staining of peripheral blood cells 
isolated 15 days after BMT from mice receiving Hrb+/+ 
and Hrb–/– MigR1– and ICN1–transduced BM cells. 
(D–E) GFP analysis and CD4+CD8+ surface staining 
of splenocytes (D) and BM cells (E) isolated from mice 
receiving Hrb+/+ and Hrb–/– ICN1–transduced BM cells. 
Numbers in GFP histograms refer to the percentage of 
GFP-positive cells. Numbers in each dot plot refer to 
the percentages in each quadrant.
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Hrb regulates p21 protein levels via transferrin uptake. Iron is impor-
tant in several cellular processes (31, 32) and particularly in cell 
cycle progression and survival. One such component that is depen-
dent upon iron is the p21 (CIP1/WAF1) protein, a cdk inhibitor 
that has been shown in various systems to halt cell cycle progres-
sion (33–37). However, there is also evidence to suggest that p21 
can promote cell cycle progression since  it  is required for the 
assembly of cyclin DCDk complexes (38) and that it serves a pro-
survival function in breast cancer (38, 39) and thymic lymphoma 
(40). Moreover, there is evidence that p21 can inhibit apoptosis 
directly by preventing activation of caspase 3 (41) or apoptosis sig-
nal–regulating kinase 1 (ASK1) (42).
Although transcript levels of p21 were unaltered, we found 
that p21 protein levels were dramatically increased after ICN1 
transduction of WT thymocytes. This induction was almost com-
pletely lacking in Hrb–/– cells (Figure 7, A and C). Importantly, 
the transcript levels of p21 were equal between Hrb+/+ and Hrb–/– 
ICN1–transduced thymocytes (Figure 7B). p21 has been shown 
to be regulated at the posttranscriptional level by intracellular 
iron status (43). Accordingly, we found that addition of increas-
ing concentrations of excess transferrin to Hrb–/– cell cultures 
resulted in the rescue of p21 protein levels to those seen in Hrb+/+ 
ICN1–transduced thymocytes (Figure 7C). To determine wheth-
er overexpression of p21 by itself could increase cell numbers 
in Hrb+/+ ICN1–transduced hematopoietic precursor cells, we 
cotransduced these cells with p21-expressing retroviral vectors 
and monitored cell numbers over a period of 7 days. We found 
a more than 4-fold increase in cell accumulation after cotrans-
duction with ICN1 and p21 retroviral vectors (Figure 7D). We 
conclude that Hrb is critically important for the induction of 
p21 protein in ICN1-expressing thymocytes, most likely via Hrb’s 
ability to enhance uptake of transferrin.
Hrb is regulated by Notch signaling in human T-ALL cell lines and is 
required for leukemia cell proliferation and survival. To determine 
whether  the observed  interplay among Notch, Hrb, and  iron 
metabolism may function in human T-ALL as well, we utilized 
the Notch-dependent T-ALL cell lines DND41, T-ALL1, KOPTK1, 
and SUPT1. GSI treatment of DND41 and T-ALL1 cells decreased 
the transcript levels of Hrb (Figure 8A), as was observed with the 
mouse T6E cell line (Figure 2A). Knockdown of Hrb resulted in a 
decreased accumulation of human T-ALL cells as well as decreased 
survival, as assessed by annexin V/PI staining (Figure 8, B–D). Our 
data suggest that Hrb plays a role in the efficient utilization of 
iron via transferrin. Thus, inefficient use of iron in Hrb-depleted 
cells should confer greater sensitivity to the iron chelator desfer-
rioxamine (DFO). Indeed, reducing Hrb levels in DND41 cells 
resulted in greater sensitivity to iron chelation (Figure 8E). Con-
sistent with the increased surface levels of CD71 in Hrb–/– cells, 
treatment with DFO at 2.0 μM in KOPTK1 cells resulted in sig-
nificantly greater surface CD71 (Figure 8F).
Iron is critical for T cell precursor development and for ICN1-induced 
leukemogenesis. To determine whether iron itself is required for thy-
mocyte development, we depleted thymocyte-OP9DL1 cocultures 
of iron by addition of DFO. This caused a dramatic loss of thy-
mocyte numbers (Figure 9A). Interestingly, Hrb–/– DN cells were 
more sensitive to depletion of iron with DFO, consistent with their 
reduced ability to utilize iron-loaded transferrin.
Together, the results above indicated a critical role for Hrb in 
mediating in vitro survival of ICN1-transduced T cell precursors 
and human T-ALL cell lines, by driving efficient utilization of iron. 
Reduced iron uptake might similarly explain the decreased inci-
dence (Figure 3A) or delay in development (Figure 4B) of T-ALL 
in mice lacking Hrb. If so, suppression of iron uptake in WT mice 
might delay their development of T-ALL. We reasoned that placing 
Figure 5
Hrb is required for growth and survival of ICN1-transduced hematopoietic and T cell precursors. (A) GFP-positive total cell number of Hrb+/+ 
ICN1–, Hrb–/– ICN1–, and Hrb–/– ICN1+Hrb–transduced hematopoietic precursor cells cocultured on OP9 stromal beds and harvested 7 days after 
transduction. (B) GFP-positive and annexin V and/or PI-positive percentages in Hrb+/+ ICN1–, Hrb–/– ICN1–, and Hrb–/– ICN1+Hrb–transduced 
hematopoietic precursor cells 7 days after transduction. (C) GFP-positive cell number of Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced thymo-
cytes grown on OP9DL1 stromal beds, harvested 5 days after transduction, and stained with antibodies to CD4 and CD8 to determine numbers in 
the CD4–CD8– DN, CD4–CD8+ ISP (CD8 ISP), or CD4+CD8+ DP subsets. (D) Western blot of lysates prepared from Hrb+/+ and Hrb–/– MigR1– and 
ICN1–transduced hematopoietic precursors (left) and Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced T cell precursors (right) blotted for Hrb 
(clone H-300) and actin (loading control). Data are shown as mean ± SD. *P < 0.05; ***P < 0.001.
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recipient mice on a low-iron diet would reduce their total body 
iron stores and decrease availability of the iron to developing leu-
kemic blasts. Cohorts of WT mice transplanted with WT ICN1–
transduced BM cells were placed on either a low-iron diet or nor-
mal mouse chow for up to 48 days. Mice that were transplanted 
with control (MigR1-transduced) BM cells on the low-iron diet 
engrafted, survived, and appeared well, although they did develop 
iron-deficiency anemia (hemoglobin 7.8 g/dl and mean corpus-
cular volume [MCV] 43.9 femtoliters [fL], compared with control 
mice with hemoglobin of 11.7 g/dl and MCV 47.9 fL). Remark-
ably, mice transplanted with ICN1-expressing BM demonstrated 
significantly delayed death from ICN1-induced leukemogenesis if 
they were maintained on the iron-restricted diet (P = 0.0001 by 
Mantel-Cox log rank analysis) (Figure 9B).
Discussion
We report an important role for Hrb in T-ALL by using mice with 
conditional deletion of CBP and mice transplanted with ICN1-
transduced BM. Our data demonstrate that Hrb upregulation 
occurs in the vast majority of CBP-null T cell lymphomas, as a 
Figure 6
Hrb loss leads to increased surface TfR (CD71) and inefficient transferrin uptake in the context of oncogenic Notch signaling. (A) Surface levels 
of TfR (CD71) on Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced thymocytes cocultured on OP9DL1 stromal beds. (B) Surface levels of CD71 
on Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced hematopoietic precursor cells cocultured on OP9 stromal beds. (C) Uptake of 10 μg/ml Alexa 
Fluor 647–conjugated transferrin in Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced DP thymocytes. (D) Uptake of Alexa Fluor 647–conjugated 
transferrin (0–50 μg/ml) in Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced DP thymocytes. Uptake experiments repeated several times with 
representative graphs shown here. Each point on the curves represents an independently transduced well in the experiment. (E) Hrb+/+ and 
Hrb–/– ICN1–transduced GFP-positive hematopoietic precursors with and without holo-Tf addition. (F) Surface CD71 levels on GFP-positive 
Hrb+/+ and Hrb–/– ICN1–transduced hematopoietic precursors treated as in panel E. (E–F) Hrb+/+ and Hrb–/– 10 μg/ml holo-Tf samples were com-
pared with respective 0 μg/ml holo-Tf samples. (G) Western blot of lysates prepared from Hrb+/+ and Hrb–/– MigR1–transduced thymocytes and 
Hrb+/+ and Hrb–/– ICN1–transduced thymocytes grown on OP9DL1 cocultures in the presence of increasing concentrations of holo-Tf. Lysates 
blotted for TfR: short exposure (top); longer exposure (bottom); and actin (loading control). DN, CD4–CD8– DN; CD8 ISP, CD4–CD8+ ISP; DP, 
CD4+CD8+ DP. Data are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
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downstream effect of activated Notch. Several important Notch 
target genes have been identified since its discovery as a potent 
oncogene (44). The majority of these target genes play crucial roles 
in physiologic Notch signaling. Here, we identify Hrb as a direct 
transcriptional target of Notch. Hrb is not required for physiolog-
ic Notch signaling, since thymocyte development is completely 
normal in Hrb–/– mice. On the other hand, Hrb is clearly required 
for efficient Notch-induced lymphomagenesis, as evidenced by a 
delay in ICN1-induced T-ALL and a reduction in tumor incidence 
in the CBP-null mouse model. Clues from in vitro proliferation 
and development clearly suggested a failure to achieve optimal 
cell survival under the influence of ICN1 expression. Indeed, Hrb 
was required for survival of Notch-dependent human T-ALL cell 
lines in culture. Oncogenes (such as myc) that are upregulated by 
Notch are known to activate the cellular suicide program (45). 
ICN1 itself simultaneously offsets some of these effects through 
inhibition of p53 (46). However, lacking Hrb expression, the drive 
to apoptosis was inadequately suppressed, and we suspect this is 
a major cellular mechanism by which Hrb supports Notch-medi-
ated lymphomagenesis.
Our data argue that Hrb facilitates oncogenesis by enhancing the 
ability of cells to take up transferrin. According to this model, in Hrb–/– 
cells, particularly under the conditions of enforced proliferation 
driven by ICN1, iron uptake does not keep pace with the increased 
metabolic requirements of transformed cells, resulting in a state of 
iron depletion. This in turn induces the synthesis of CD71 in a failed 
attempt to acquire more iron from the cell surroundings. If this is 
unsuccessful, cell survival is compromised, leading to apoptosis 
(Figure 9C). In such a situation, leukemic progenitor cells cannot 
survive the stress of transformation in the face of relative iron starva-
tion, which could explain the reduced incidence of T-ALL in CBP-
null mice. In the case of ICN1-transduced BM, the oncogene is of 
such high potency that eventually even the severe defect of Hrb loss 
in transformed cell viability would ultimately be overcome by a rare 
secondary event that could bypass the apoptotic response. However, 
in the presence of supra-normal levels of transferrin in culture, Hrb is 
no longer required, as cells can compensate for inefficient uptake. It 
is likely that competition for transferrin within the BM is much more 
intense than that in vitro, thus amplifying the effect in vivo.
Notch activation has previously been shown to upregulate surface 
transferrin receptor (TfR) (47), and TfR has recently been shown to 
be a direct transcriptional target of c-myc (48), itself a direct target of 
Notch (14). Our work provides the first description at the molecu-
lar level of how oncogenic Notch signaling directs the transformed 
cell to meet increased metabolic demands for needed iron through 
upregulation of Hrb to accelerate transferrin uptake. Hrb was previ-
ously shown to be essential for efficient transferrin uptake by the 
use of knockdown experiments (12). Additionally, a role for Hrb in 
clathrin-mediated relocalization of VAMP7 from the cell surface to 
the endocytic compartment was demonstrated by Pryor et al. (11). 
Here, using Hrb–/– mice, we provide an important context to Hrb’s 
role in clathrin-dependent endocytosis of cell surface TfR, down-
stream of oncogenic Notch signaling. Also, by utilizing a knockdown 
approach in Notch-dependent T-ALL cell lines, we demonstrate the 
importance of Hrb in the viability of human leukemia cells.
How does the failure to efficiently take up holo-transferrin lead 
to the death of ICN1-expressing thymocytes? Although it could 
result from a general metabolic failure as iron-containing enzymes 
become depleted, we suspect a more direct cause may be the fail-
ure to upregulate the p21 protein after ICN1 transduction. Much 
Figure 7
Addition of excess holo-transferrin restores p21 protein levels in ICN1-transduced Hrb–/– T cell precursors. (A) Western blot of lysates prepared from 
Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced thymocytes grown on OP9DL1 cocultures and harvested 5 days after transduction. Lysates blotted 
for p21 and actin (loading control). (B) Quantitative RT-PCR of mRNA isolated from the Hrb+/+ and Hrb–/– MigR1– and ICN1–transduced thymocytes 
grown as in panel A. (C) Western blot of lysates from Figure 6G blotted for p21 and actin (loading control). (D) GFP-positive cell number of ICN1- and 
ICN1+p21–transduced WT hematopoietic precursors cocultured on OP9 stromal beds for 10 days. Data are shown as mean ± SD. ***P < 0.001.
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focus has been placed on the role of p21 as a tumor-suppressor pro-
tein due to its cell cycle inhibitory functions, but there is consider-
able evidence for a prosurvival function of p21 (49). p21 appears 
to have a special prooncogenic function in thymocytes because the 
incidence of T cell lymphomas is significantly decreased in p21 
knockout mice (40). How p21 is regulated by activated Notch in T 
cell precursors is not known, but in cells of the renal glomerulus, 
it was shown to be due to p53-dependent upregulation of the p21 
mRNA (50), and in keratinocytes, p21 is a direct transcriptional 
target of Notch1 activation (51). Interestingly, we found the tran-
script levels of p21 to be equal in ICN1-transduced cells, regard-
less of their Hrb status. These results suggest a posttranscriptional 
or posttranslational mechanism of regulation of p21. Fu et al. 
demonstrated that iron chelation leads to the ubiquitin-indepen-
dent proteasomal degradation of p21 protein and a concomitant 
decrease in nucleocytoplasmic transport of p21 mRNA (43). It is 
likely that deficiency in iron utilization in Hrb–/– cells similarly 
prevented the ICN1-induced upregulation of p21 that occurs at 
the posttranscriptional level in WT cells, since addition of excess 
transferrin restored p21 accumulation. What role p21 plays in 
ICN1-induced leukemogenesis is not yet clear, but it is likely that 
p21 stabilization serves a prosurvival function, as has been shown 
in other T cell lymphomas (40). Indeed, coexpression of p21 with 
ICN1 led to a significant increase in cell accumulation.
Figure 8
Hrb is regulated by Notch signaling in human T-ALL cell lines and is required for cell proliferation and survival. (A) Quantitative RT-PCR analysis 
demonstrating the downregulation of Hrb following treatment with GSI (1 μM). Human T-ALL cell lines DND41 and T-ALL1 were treated with DMSO 
or GSI for 24 hours and 72 hours, respectively. Total RNA was prepared for reverse transcription and human Hrb mRNA abundance was mea-
sured by quantitative RT-PCR. (B) Nontarget control (NTC) and Hrb knockdown (HO22/HO23) stably transduced T-ALL cell lines were seeded at 
100,000 cells/well and cultured for 7 days. Total cell numbers were counted based on forward and side scatter. (C) Western blot of lysates prepared 
from KOPTK1 and SUPT1 cell lines stably transduced with nontarget control and HO22/HO23 Hrb knockdown lentiviral vectors. Membranes were blot-
ted with Hrb (clone H-300) and GAPDH (loading control). (D) Nontarget control and Hrb knockdown (HO22/HO23) stably-transduced T-ALL cell lines 
were seeded at 100,000 cells/well and cultured for 7 days. Cell survival was assessed using annexin V/PI staining. (E) DFO sensitivity of DND41 cells 
stably transduced with nontarget control or HO22. nontarget control or HO22 DND41 T-ALL cells were treated with 0, 25, or 50 μM DFO for 4 days. 
Following treatment, total cell numbers were acquired based on forward/side scatter and normalized to untreated. (F) Surface CD71 levels on NTC 
and HO23 stably transduced KOPTK1 cells treated with 0, 1.0, and 2.0 μM DFO. Data are shown as mean ± SD. **P < 0.01; ***P < 0.001.
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The concept of nononcogene addiction (NOA) (52, 53) is attrac-
tive in this case, as we suspect that Notch-transformed cells are 
“addicted” to their high levels of Hrb. Identification of gene prod-
ucts that in and of themselves are not oncogenic, but that are 
required for efficient tumor growth, underlies this concept. Hrb 
overexpression is not known to be tumorigenic but is evidently 
required for efficient T cell malignancy. It has been proposed that 
discovering pathways that allow cancer cells to more efficiently 
metabolize nutrients may ultimately result in better treatments 
for cancer. Indeed, depriving cancer cells of iron with the use of an 
iron chelator (54, 55) or limiting the iron intake of mice with can-
cer (56) has previously been shown to inhibit cancer cell growth. 
This work provides what we believe is new evidence for the role of 
iron in the development of Notch-induced leukemias and raises 
the possibility that Hrb could be an attractive molecular target for 
T-ALL therapy, as it is not required for normal cell development, 
has a significant role in efficient iron uptake in Notch-transformed 
cells, and its loss sensitizes cells to iron depletion.
Additionally, our data suggest that the iron status of leukemia 
patients may be a contributory factor  in the disease outcome. 
Intensified chemotherapeutic protocols for childhood leukemia 
have necessitated more frequent blood transfusions, which can pre-
dispose patients to iron overload (57). It may thus be detrimental 
to transfuse packed red blood cells into these patients, with little 
regard for the resulting iron overload that ensues. Although not 
thought to cause direct tissue damage as does occur in more chron-
ically transfused patients, such as those with thalassemia and sickle 
cell anemia (58, 59), administration of a high iron load concurrent-
ly with chemotherapy may serve to enhance the survival properties 
of residual malignant cells. Future clinical studies should explore 
Figure 9
Iron is critical for T cell precursor development and for ICN1-induced leukemogenesis. (A) Hrb+/+ and Hrb–/– CD4–CD8– DN cells were seeded 
on OP9DL1 stromal beds. DFO was added at 0.5 and 5.0 μM 2 days after cells were plated. Total cell numbers were counted 2 days after treat-
ment. Fold reduction in cell number was calculated in relationship to 0 μM DFO. (B) Lethally irradiated recipient mice received 25,000 ICN1-
transduced BM cells. 7 mice were given normal feed, and 8 mice were given a low-iron diet immediately after transplant and were maintained 
on their respective diets. Additionally, 5 recipient mice that were transplanted with 25,000 MigR1-transduced BM cells were kept on the same 
low-iron diet as controls. Maintenance on a low-iron diet delayed death by ICN1-induced leukemogenesis (P = 0.0001 using log-rank Mantel-Cox 
test). (C) Model for the role of Hrb in oncogenic Notch signaling: Notch activation after loss of CBP or somatic mutation of Notch1 can lead to Hrb 
upregulation and cell transformation. Hrb upregulation is required for efficient transferrin uptake, resulting in increased intracellular iron for the 
transformed cell. This increase in iron uptake leads to increased p21 protein levels. Together, these molecular changes contribute to the survival 
and proliferation of the Notch-transformed cell, resulting in leukemia. Data are shown as mean ± SD. ***P < 0.001.
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whether appropriate timing of blood transfusions may improve 
outcomes in leukemia or other cancer therapeutic trials.
Methods
Mice. CBP conditional knockout mice and MMTV-Cre mice were previous-
ly described (6). Hrb+/– mice on the background of MMTV-Cre/CBPflox/flox 
were intercrossed to generate Hrb+/+ and Hrb–/– cohorts in the background 
of CBP deletion. ICN1/CBP-null mice were generated by mating CBPflox/flox 
mice to mice with ICN1 downstream of a floxed STOP sequence, which 
have been previously described (13). These mice were, in turn, mated to 
MMTV-Cre mice to activate ICN1 expression and delete CBP. Recipients 
for the BMT experiments were 4- to 8-week-old female C57BL/6 mice (Jack-
son Laboratory). Mice were observed daily for any signs of poor health. 
Sick mice were sacrificed and screened for tumors. All mouse studies were 
approved by the Mayo Clinic Animal Care and Use Committee.
Flow cytometry. Antibodies were from BD Biosciences — Pharmingen. 
Cells were stained for surface expression of the following markers using the 
antibodies in parentheses: CD4 (RM4-5), CD8 (53-6.7), CD25 (7D4), CD44 
(IM7), and CD71 (C2). Cell survival was assessed using annexin V–Cy5 and 
PI staining (BD Biosciences — Pharmingen). Viable cells were gated accord-
ing to their forward scatter and side scatter profiles.
Western blotting. Lysates from CBP-null lymphomas were prepared by 
snap-freezing lymphoma tissue in liquid N2. Snap-frozen lymphoma tis-
sue or PBS-washed T cell precursors and hematopoietic precursors grown 
on OP9/OP9DL1 stromal beds were lysed in NP-40 lysis buffer (1% NP-40, 
0.5% sodium deoxycholate, 5 mM EDTA, 50 mM Tris, pH 7.4, 150 mM 
NaCl, and a protease inhibitor cocktail from Roche). Blots were probed with 
antibodies that recognize Notch1 (mN1a; Santa Cruz Biotechnology Inc.), 
gamma-secretase cleaved Notch1 (VAL1744; Cell Signaling), Hrb (H-300; 
Santa Cruz Biotechnology Inc.), p21 (M-19, Santa Cruz Biotechnology Inc.), 
CD71 (Invitrogen), Actin (Millipore), and GAPDH (Trevigen). The affinity-
purified Hrb antibody (clone 386–562) was previously described (10).
Real-time RT-PCR. 1 μg total RNA isolated from T6E12 cells or KOPTK1 
and TALL1 T-ALL cell lines was reverse-transcribed with SuperScript II 
(Invitrogen) according to the manual. All quantitative RT-PCR reactions 
were performed in triplicate. Primer sequences for real-time PCRs were as 
follows: human Hrb forward, 5′-TTCATCAAGTGTGCCTGCTC; human 
Hrb  reverse,  5′-GCATTGGTCTGAAATGGGTT; mouse Hrb  forward, 
5′-AGCCCTGGCAGAGTTAGACA-3′; mouse Hrb reverse, 5′-CAGGCACT-
GTTCCAAAGACA-3′; 18S rRNA forward, 5′-GCGCCGCTAGAGGTGAAAT-
3′; and 18S rRNA reverse, 5′-GGCGGGTCATGGGAATAAC-3′. Hrb and 18S 
rRNA primers were used at a final concentration of 0.4 μM. Real-time ampli-
fication was performed with TaqMan universal PCR Master Mix (Applied 
Biosystems) and analyzed on the ABI Prism 7900 (Applied Biosystems).
ChIP assay. ChIP was performed using ChIP assay kits (Upstate Biotech-
nology) as previously described (14). DNA was recovered for quantitative 
RT-PCR using the SYBR Green system on the ABI 7900HT Sequence Detec-
tion System (Applied Biosystems) with the following primers: (a) Hrb (–32 K) 
forward, 5′-TTTGGGTGAACATTCCTGACAA-3′; (b) Hrb (–32 K) reverse, 
5′-GGCACTGAGAAATGCGTGTG-3′; (c) Hrb (180 bp) forward, 5′-CTCC-
GGCAGCCTGTGAGT-3′; (d) Hrb (180 bp) reverse, 5′-CCGGCCAAAGAG-
CAAGAG-3′; (e) hes1 promoter forward, 5′-CGTGTCTCTTCCTCCCATTG-
3′; and (f) hes1 promoter reverse, 5′-CCAGGACCAAGGAGAGAGGT-3′. Each 
sample was independently prepared at least 2 times and run in duplicate.
OP9/OP9DL1 cocultures. OP9 and OP9DL1 cells were a gift from Kay 
Medina (Department of Immunology, Mayo Clinic). Magnetic bead-sorted 
CD4–CD8– DN T cell precursors were isolated from total mouse thymo-
cytes using CD4 and CD8 MACS microbead isolation kits (Miltenyi Biotec). 
Hematopoietic precursors were isolated from total BM preparations using 
the Lineage Cell Depletion Kit (Miltenyi Biotec). Precursors were cocultured 
on irradiated OP9 and OP9DL1. Recombinant murine IL-7 and FLT3L 
(Peprotech) were added to cultures at a final concentration of 5 ng/ml.
Retroviral vectors and transductions. The MigR1 empty vector, MigRI–
DNMAML1(residues 13–74), and Mig-ICN1 constructs were previously 
described (15). Murine Hrb and p21 (CDKN1a) expression vectors carried 
the respective cDNA in the XhoI site of MigRI. Production of high-titer 
ecotropic retroviruses for the T6E12 cell transductions has been described 
(60). GSI was a gift from Yueming Li (Department of Molecular Pharma-
cology & Chemistry, Memorial Sloan-Kettering Cancer Center, New York, 
New York, USA). PLAT-E cells used to package the retroviral vectors for 
transductions were a kind gift from Kay Medina (Department of Immu-
nology, Mayo Clinic). OP9/OP9DL1 cocultures of T cell precursors or 
hematopoietic precursors were spin-infected with retroviral supernatants 
at room temperature for 2 hours at 1200 g.
Lentiviral production and transduction of the DND41 T-ALL cell line. Lentiviral 
vectors containing short hairpins to a nontarget control (NTC; Sigma-
Aldrich) and human Hrb (HO22; Sigma-Aldrich) were produced in 293FT 
cells (Sigma-Aldrich). T-ALL cell lines (gift from Thomas Look, Depart-
ment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Mas-
sachusetts, USA) were spin-infected with viral supernatants at 1200 g for 
1 hour at room temperature.
Transferrin uptake assay and holo-transferrin addition. T cell precursors cocul-
tured on OP9DL1 cells were incubated with 10 μg/ml Alexa Fluor 647–
conjugated human holo-transferrin (Invitrogen) to prebind transferrin. 
Labeled transferrin was competed off by incubation with a 50-fold excess of 
unlabeled human holo-transferrin (Sigma-Aldrich). Samples were stained 
with additional antibodies and analyzed by flow cytometry for transfer-
rin uptake. For experiments in which excess human holo-transferrin was 
added, 48 hours after transduction of T cell precursors with MigR1 or 
ICN1, cells were incubated for an additional 48 hours with 10 to 150 μg/ml 
holo-transferrin. DFO and FAC (Sigma-Aldrich) were added to cell cultures 
at the indicated concentrations.
BM transduction and transplantation. Transduction of BM cells harvest-
ed from 5-FU–treated mice and subsequent transplantation has been 
described  (18). Complete blood counts were done using a Hemavet 
950FS (Drew Scientific Inc.). Low iron mouse feed was from Harlan. 
Mice showing poor grooming, difficulty getting to feed, and general 
lethargic behavior were euthanized. Splenocytes and BM were isolated 
from these mice for analysis.
Statistics. Where appropriate, all statistical analyses were carried out using 
GraphPad Prism software using a 2-tailed Student’s t test or 2-way ANOVA 
with Bonferroni’s post-tests. P ≤ 0.05 was considered significant. All experi-
ments were performed in triplicate and are presented as mean ± SD.
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